We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

LPTX Leap Therapeutics Inc

0.09 (4.0%)
Dec 01 2023 - Closed
Delayed by 15 minutes


Draw Mode:

Volume 189,264
Bid Price 2.12
Ask Price 2.44
News -
Day High 2.39


52 Week Range


Day Low 2.16
Company Name Stock Ticker Symbol Market Type
Leap Therapeutics Inc LPTX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.09 4.0% 2.34 20:00:00
Open Price Low Price High Price Close Price Prev Close
2.23 2.16 2.39 2.34 2.25
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
1,316 189,264 $ 2.27 $ 430,377 - 1.235 - 10.20
Last Trade Time Type Quantity Stock Price Currency
18:56:26 8 $ 2.23 USD

Leap Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
59.06M 25.57M - 0 -54.6M -2.14 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Leap Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No LPTX Message Board. Create One! See More Posts on LPTX Message Board See More Message Board Posts

Historical LPTX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.882.92992.102.45329,165-0.54-18.75%
1 Month1.683.021.322.16314,5010.6639.29%
3 Months1.973.021.2351.76292,9680.3718.78%
6 Months10.0010.201.2353.93390,880-7.66-76.6%
1 Year5.98810.201.2354.91595,843-3.65-60.92%
3 Years16.0041.701.23520.411,230,148-13.66-85.38%
5 Years37.7041.701.23520.12959,702-35.36-93.79%

Leap Therapeutics Description

Leap Therapeutics Inc is a biopharmaceutical company developing novel therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. Its clinical stage program is DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1. DKK1 is a protein that regulates the Wnt signaling pathways and enables tumor cells to proliferate and spread, as well as suppresses the immune system from attacking the tumor. The company is studying DKN-01 in multiple ongoing clinical trials in patients with esophagogastric cancer, hepatobiliary cancer, gynecologic cancers, or prostate cancer. Its other clinical studies include P100, P102, P204,and P205.

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 |